- Report
- September 2025
- 125 Pages
Global
From €5260EUR$5,950USD£4,579GBP
- Report
- September 2025
- 250 Pages
Global
From €3969EUR$4,490USD£3,456GBP
- Report
- April 2025
- 200 Pages
Global
From €3969EUR$4,490USD£3,456GBP
- Report
- September 2025
- 145 Pages
Global
From €2651EUR$2,999USD£2,308GBP
- Report
- June 2025
- 400 Pages
Global
From €4375EUR$4,949USD£3,809GBP
- Report
- March 2024
- 200 Pages
Global
From €3669EUR$4,150USD£3,194GBP
- Report
- April 2023
- 112 Pages
Global
From €4199EUR$4,750USD£3,656GBP
- Report
- July 2022
- 199 Pages
Global
From €3934EUR$4,450USD£3,425GBP
Doxil is a chemotherapy drug used to treat ovarian cancer. It is a liposomal formulation of the drug doxorubicin, which is an anthracycline antibiotic. Doxil is used to treat advanced ovarian cancer, as well as other types of cancer, such as breast cancer, Kaposi's sarcoma, and multiple myeloma. It is administered intravenously and works by interfering with the growth of cancer cells.
Doxil is a widely used drug in the treatment of ovarian cancer, and is often used in combination with other drugs. It is generally well tolerated, with few side effects. Common side effects include nausea, vomiting, hair loss, and fatigue.
The Doxil market is highly competitive, with several companies offering the drug. Some of the companies in the market include Janssen Pharmaceuticals, Sun Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more